Patent ID: 9587281
Date: 2017-03-07
CPC Classifications: A61K,C07K,C12Q,G01N

Claim:
1. A method for determining whether a subject having a multiple myeloma is sensitive to a treatment with pomalidomide or a pharmaceutically acceptable salt thereof, wherein said method comprises (a) obtaining a multiple myeloma sample from the subject; (b) determining the level of an isoform of CRBN in the multiple myeloma sample, the isoform of CRBN comprising a single exon 6 deletion and comprising exons 1-5 and 7-11; (c) diagnosing the subject as being sensitive to the treatment with pomalidomide or a pharmaceutically acceptable salt thereof if the isoform of CRBN was determined to be less than a baseline level in the multiple myeloma sample; and (d) administering an effective amount of pomalidomide or a pharmaceutically acceptable salt thereof to the subject diagnosed as being sensitive to the treatment with pomalidomide or a pharmaceutically acceptable salt thereof.